Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO...Collaboration and License Agreement • August 6th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this“Amendment”) is effective as of April 3, 2024 (the “Amendment Effective Date”) by and between VOYAGER THERAPEUTICS, INC., a Delaware corporation (“Voyager”), having its principal place of business at 75 Hayden Avenue, Lexington, MA 02421, and NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (“Neurocrine”), having its principal place of business at 12780 El Camino Real, San Diego, CA 92130. Voyager and Neurocrine may each be referred to herein individually as a “Party” and collectively as the “Parties”.
